TY - JOUR
T1 - Preventive treatment of headache with slow-release dihydroergotamine
T2 - Comparison of dosage protocols
AU - Buscaino, G. A.
AU - Sorge, F.
AU - Bussone, G.
AU - Frediani, F.
AU - Giacovazzo, M.
AU - Martelletti, P.
AU - Manzoni, G. C.
AU - Martucci, N.
AU - Nappi, G.
AU - Micieli, G.
AU - Puca, F. M.
AU - Genco, S.
AU - Sacquegna, T.
AU - Dalla Volta, G.
PY - 1991
Y1 - 1991
N2 - Ninety patients (63 women and 27 men; mean age, 37 years) suffering from common migraine were treated, according to a double-blind experimental scheme, with a new formulation of slow-release dihydroergotamine (DHE-CP) either 5 mg BID or 10 once daily for two months. The results show the preventive treatment to be effective, with a significant reduction (P <0.01 between times) in the severity and frequency of headache and the associated symptoms, independent of the dosage scheme. Tolerance was also considered to be good in that only 4% of the patients (three patients receiving DHE-CP BID and one patient once daily) had to discontinue treatment due to side effects. The daily dosage of DHE-CP may be administered either in a single dose or twice a day with comparable therapeutic effectiveness and safety.
AB - Ninety patients (63 women and 27 men; mean age, 37 years) suffering from common migraine were treated, according to a double-blind experimental scheme, with a new formulation of slow-release dihydroergotamine (DHE-CP) either 5 mg BID or 10 once daily for two months. The results show the preventive treatment to be effective, with a significant reduction (P <0.01 between times) in the severity and frequency of headache and the associated symptoms, independent of the dosage scheme. Tolerance was also considered to be good in that only 4% of the patients (three patients receiving DHE-CP BID and one patient once daily) had to discontinue treatment due to side effects. The daily dosage of DHE-CP may be administered either in a single dose or twice a day with comparable therapeutic effectiveness and safety.
UR - http://www.scopus.com/inward/record.url?scp=0025873863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025873863&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0025873863
SN - 0011-393X
VL - 49
SP - 925
EP - 935
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
IS - 6
ER -